Select Publications
Conference Papers
, 2008, 'Proteinuria is associated with a 50% increased risk of coronary heart disease: a meta-analysis of prospective cohort studies', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 593 - 593
, 2008, 'THE RENAL CHARACTERISTICS OF PATIENTS WITH A HISTORY OF LITHIUM EXPOSURE AS DETERMINED BY FORMAL RENAL FUNCTION TESTING', in NEPHROLOGY, WILEY-BLACKWELL, pp. A145 - A145
, 2007, 'LOWER BLOOD PRESSURE AND THE RISK OF STROKE IN CHRONIC KIDNEY DISEASE: RESULTS OF THE PROGRESS TRIAL', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, Adelaide, pp. 173 - 173, presented at 29th Annual Scientific Meeting of the High-Blood-Pressure-Research-Council-of-Australia, AUSTRALIA, Adelaide, 05 December 2007 - 08 December 2007
, 2007, '20 YEAR OUTCOMES OF THE AUSTRALIAN MULTICENTRE RANDOMISED TRIAL OF CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION', in NEPHROLOGY, WILEY-BLACKWELL, pp. A19 - A19, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652500075&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, 'THE EFFICACY OF LOWER BLOOD PRESSURE GOALS ON THE PREVENTION OF STROKE IN CHRONIC KIDNEY DISEASE: DATA FROM THE PROGRESS STUDY', in NEPHROLOGY, WILEY-BLACKWELL, pp. A31 - A31, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652500122&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, '20 year outcomes of the Australian multicentre randomised trial of cyclosporine withdrawal in renal transplantation.', in AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL PUBLISHING, CA, San Francisco, pp. 206 - 207, presented at Annual American Transplant Congress, CA, San Francisco, 05 May 2007 - 09 May 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000246370200232&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2007, 'PROTEINURIA AS A PREDICTOR OF CORONARY HEART DISEASE - A SYSTEMATIC REVIEW', in NEPHROLOGY, WILEY-BLACKWELL, pp. A31 - A31
, 2007, 'PROTEINURIA AS A PREDICTOR OF STROKE - A SYSTEMATIC REVIEW', in NEPHROLOGY, WILEY-BLACKWELL, pp. A31 - A31
, 2006, 'COST EFFECTIVENESS OF SCREENING FOR THE EARLY DIAGNOSIS AND TREATMENT OF RISK FACTORS FOR CHRONIC KIDNEY DISEASE: A MARKOV MONTE CARLO MICROSIMULATION USING MARCK-E (MODEL FOR THE ASSESSMENT OF RISK FACTORS FOR CHRONIC KIDNEY DISEASE - ECONOMICS)', in NEPHROLOGY, WILEY-BLACKWELL, pp. A9 - A9, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652400034&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2006, 'THE RELATIONSHIP BETWEEN CHRONIC KIDNEY DISEASE AND INDIVIDUAL-LEVEL SOCIOECONOMIC FACTORS: THE THREE COUNTRY KIDNEY DISEASE STUDY (3CKD)', in NEPHROLOGY, WILEY-BLACKWELL, pp. A13 - A14, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652400053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2006, 'THE ROLE OF NOCTURNAL HAEMODIALYSIS AND ARTERIAL STIFFNESS', in NEPHROLOGY, WILEY-BLACKWELL, pp. A30 - A30, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208652400121&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2006, 'Reductions in the risks of vascular events and stroke in patients with and without chronic kidney disease; New data from the PROGRESS trial', in HYPERTENSION, LIPPINCOTT WILLIAMS & WILKINS, AUSTRALIA, pp. 1475 - 1475, presented at Annual Scientific Meeting of the High-Blood-Pressure-Research-Council-of-Australia, AUSTRALIA
, 2006, 'REDUCTIONS IN THE RISKS OF VASCULAR EVENTS AND STROKE IN PATIENTS WITH AND WITHOUT CHRONIC KIDNEY DISEASE; NEW DATA FROM THE PROGRESS TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. A21 - A21
, 2006, 'THE PREDICTIVE ABILITY OF DIFFERENT MEASURES OF KIDNEY FUNCTION: NEW DATA FROM THE PROGRESS STUDY', in NEPHROLOGY, WILEY-BLACKWELL, pp. A46 - A46
, 2005, 'Dialysis adequacy (HD) guidelines: Dose of haemodialysis', in Nephrology, pp. S61 - S63, http://dx.doi.org/10.1111/j.1440-1797.2005.00464_1.x
, 2003, 'Sirolimus: A single center experience in combination with calcineurin inhibitors', in Transplantation Proceedings, pp. S99 - S104, http://dx.doi.org/10.1016/S0041-1345(03)00219-7
Conference Posters
, 2022, 'POS-546 EFFICACY AND SAFETY OF IPTACOPAN IN IgA NEPHROPATHY: RESULTS OF A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY AT 6 MONTHS', Vol. 7, pp. S236 - S236, http://dx.doi.org/10.1016/j.ekir.2022.01.577
, 2020, '1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)', ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1130-p
, 2020, 'The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS', ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-139-LB
, 2020, 'EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION', Chicago, IL, Vol. 75, pp. 221 - 221, presented at Conference of American-College-of-Cardiology (ACC) / World Congress of Cardiology (WCC), Chicago, IL, 28 March 2020 - 30 March 2020, http://dx.doi.org/10.1016/S0735-1097(20)30848-2
Conference Presentations
, 2022, 'Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial', http://dx.doi.org/10.2337/db22-747-P
, 2020, 'Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE', presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-26-OR
Conference Abstracts
, 2024, 'Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, SWEDEN, Stockholm, Vol. 39, presented at 61st Congress of European-Renal-Association (ERA), SWEDEN, Stockholm, 23 May 2024 - 26 May 2024, http://dx.doi.org/10.1093/ndt/gfae069.141
, 2024, 'EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, SWEDEN, Stockholm, Vol. 83, pp. 699 - 700, presented at 61st Congress of European-Renal-Association (ERA), SWEDEN, Stockholm, 23 May 2024 - 26 May 2024
, 2024, 'Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, SWEDEN, Stockholm, Vol. 39, pp. I255 - I256, presented at 61st Congress of European-Renal-Association (ERA), SWEDEN, Stockholm, 23 May 2024 - 26 May 2024
, 2024, 'SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL', in AMERICAN JOURNAL OF KIDNEY DISEASES, W B SAUNDERS CO-ELSEVIER INC, CA, Long Beach, Vol. 83, pp. S114 - S114, presented at Spring Clinical Meeting of the National Kidney Foundation, CA, Long Beach, 14 May 2024 - 18 May 2024
, 2024, 'ALBUMINURIA, KIDNEY FUNCTION AND HEART FAILURE IN TYPE 2 DIABETES: A SECONDARY ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 29, pp. 75 - 75
, 2022, 'CANAGLIFLOZIN AND DIURETIC USE IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE: INSIGHTS FROM THE CREDENCE TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 15 - 15, http://dx.doi.org/10.26190/unsworks/28407
, 2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney outcome guided by HbA1c and predicted risk of kidney failure', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S278 - S278, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022
, 2022, 'Novel subgroups of patients with type 2 diabetes show differential cardiovascular and kidney benefits with canagliflozin: a data-driven proteomic cluster analysis', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 65, pp. S132 - S132, presented at 58th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 19 September 2022 - 23 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000841795900252&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2022, 'Interleukin-6 and Cardiovascular Outcomes in Patients with Type 2 Diabetes: A Post Hoc Analysis of CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, Vol. 71, http://dx.doi.org/10.2337/db22-862-P
, 2022, 'FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease', in Nephrology Dialysis Transplantation, Oxford University Press (OUP), Vol. 37, http://dx.doi.org/10.1093/ndt/gfac126.002
, 2022, 'EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISONE IN IGA NEPHROPATHY: THE TESTING TRIAL', in NEPHROLOGY, WILEY, Vol. 27, pp. 14 - 14
, 2022, 'POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION', in Kidney International Reports, Elsevier BV, Vol. 7, pp. S8 - S8, http://dx.doi.org/10.1016/j.ekir.2022.01.027
, 2021, 'Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial', in DIABETOLOGIA, SPRINGER, Vol. 64, pp. 227 - 227, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000696550100443&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial', in Diabetes Obesity and Metabolism, Vol. 23, pp. 1652 - 1659, http://dx.doi.org/10.1111/dom.14386
, 2021, 'A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 36, pp. 160 - 160, presented at 58th Congress of the European-Renal-Association (ERA)-European-Dialysis-and-Transplant-Association (EDTA), ELECTR NETWORK, 05 June 2021 - 08 June 2021
, 2021, 'Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus', in Metabolism, Elsevier, Vol. 116, pp. 154509, http://dx.doi.org/10.1016/j.metabol.2020.154509
, 2020, 'GLOMERULAR DISEASE REGISTRY AND BIOBANK (GRIT)', in NEPHROLOGY, WILEY, Vol. 25, pp. 50 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200150&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO ALBUMINURIA AT BASELINE: RESULTS FROM PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE SERUM URATE LEVEL: RESULTS FROM POST HOC ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200190&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO DIABETIC KIDNEY DISEASE AT BASELINE: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200188&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'THE FILTRATION IN THE NEUROPATHY OF END-STAGE KIDNEY DISEASE (FINESSE) RANDOMISED CONTROLLED TRIAL', in NEPHROLOGY, WILEY, Vol. 25, pp. 11 - 11
, 2020, 'VARIABILITY IN EGFR AND THE RISK OF MAJOR CLINICAL OUTCOMES IN DIABETES: RESULTS FROM ADVANCE', in NEPHROLOGY, WILEY, Vol. 25, pp. 22 - 22, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S269 - S269, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600560&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Effects of canagliflozin on cardiovascular death and hospitalisation for heart failure by eGFR: integrated analyses of the CANVAS Program and CREDENCE', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S267 - S268, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000565776600558&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, Vol. 63, pp. S61 - S62, presented at 56th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), ELECTR NETWORK, 21 September 2020 - 25 September 2020, http://dx.doi.org/10.26190/unsworks/27933
, 2020, 'Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 3316 - 3316, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106303323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, ELECTR NETWORK, Vol. 41, pp. 1175 - 1175, presented at European-Society-of-Cardiology (ESC) Congress, ELECTR NETWORK, 29 August 2020 - 01 September 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial', in DIABETES, AMER DIABETES ASSOC, ELECTR NETWORK, Vol. 69, presented at 80th Scientific Sessions of the American-Diabetes-Association (ADA), ELECTR NETWORK, 12 June 2020 - 16 June 2020, http://dx.doi.org/10.2337/db20-1120-P